Stable Expression of a C-JUN Deletion Mutant in Two Malignant Mouse Epidermal Cell Lines Blocks Tumor Formation in Nude Mice
Overview
Molecular Biology
Authors
Affiliations
We have stably expressed a trans-activation suppressing deletion mutant of the human c-jun gene (TAM-67) in the malignant mouse epidermal cell lines 10Gy5 and PDV. Expression of the p26 mJUN protein blocked both constitutive and inducible transcriptional trans-activation of several AP-1 responsive reporter chloramphenicol acetyltransferase constructs. p26 mJUN was able to block both 12-O-tetradecanoylphorbol-13-acetate (TPA) and okadaic acid induced expression of the mouse stromelysin gene in 10Gy5 cells and TPA induced expression of the urokinase-type plasminogen activator gene in PDV cells as determined by Northern analyses. Both genes contain TPA response elements in their promoter regions and are known to be AP-1 responsive. The presence of p26 mJUN in nuclear extracts, as determined by Western blotting, did not detectably alter the DNA binding activity of endogenous AP-1 as determined by gel shift analysis with an oligonucleotide containing a single high affinity AP-1 binding site. UV cross-linking studies coupled with Western analyses identified DNA bound cJUN but not mJUN in nuclear extracts of stably transfected cell lines, suggesting that the mutant JUN protein may exert some of its antioncogenic effects in malignant mouse epidermal cells by a mechanism(s) not involving DNA binding. Malignant mouse epidermal cells which stably expressed the mutant JUN protein were not only inhibited in their AP-1 trans-activation response, but also in their ability to form s.c. tumors in nude mice. These results indicate that inhibition of AP-1 mediated transcriptional trans-activation alone can be sufficient to suppress the tumorigenic phenotype in a subset of malignant mouse epidermal cells.
AP-1-independent NFAT signaling maintains follicular T cell function in infection and autoimmunity.
Seth A, Yokokura Y, Choi J, Shyer J, Vidyarthi A, Craft J J Exp Med. 2023; 220(5).
PMID: 36820828 PMC: 9998660. DOI: 10.1084/jem.20211110.
Selective antagonism of cJun for cancer therapy.
Brennan A, Leech J, Kad N, Mason J J Exp Clin Cancer Res. 2020; 39(1):184.
PMID: 32917236 PMC: 7488417. DOI: 10.1186/s13046-020-01686-9.
Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse.
Cheng J, Bai A, Beckham T, Marrison S, Yount C, Young K J Clin Invest. 2013; 123(10):4344-58.
PMID: 24091326 PMC: 3784522. DOI: 10.1172/JCI64791.
S100P/RAGE signaling regulates microRNA-155 expression via AP-1 activation in colon cancer.
Onyeagucha B, Mercado-Pimentel M, Hutchison J, Flemington E, Nelson M Exp Cell Res. 2013; 319(13):2081-2090.
PMID: 23693020 PMC: 3726211. DOI: 10.1016/j.yexcr.2013.05.009.
The role of the c-Jun N-terminal Kinase signaling pathway in skin cancer.
Zhang J, Selim M Am J Cancer Res. 2012; 2(6):691-8.
PMID: 23226615 PMC: 3512184.